AOP Orphan Pharmaceuticals GmbH (AOP Health) has announced the launch of Ropeginterferon alfa-2b in patients with low-risk polycythemia vera (PV). We presented the results of an analysis evaluating the impact of individually optimized dosing regimens on therapeutic efficacy. 1These new data demonstrate that some patients with low-risk PV require and can tolerate high doses of lopeginterferon alfa-2b, and that the optimal dose varies greatly by patient. It shows that there is a difference.
First author of the abstract, Professor Heinz Gisslinger from the Medical University of Vienna, Austria, and his research team conducted this analysis in a cohort of low-risk PV patients from the large trial PROUD-PV and its extension CONTINUATION-PV. . The aim was to determine whether various baseline characteristics such as body mass index and individually optimized dose of lopeginterferon alfa-2b were associated with complete hematologic response (CHR) at 12, 24, and 72 months. The purpose of this study was to examine the effect on the state in which the blood cell count returned to normal. 1
“The results of this analysis enrich the data and add clinically relevant and important evidence that can assist healthcare professionals in making treatment decisions,” Professor Gisslinger concluded.
